Colonial River Wealth Management LLC Acquires 1,067 Shares of Eli Lilly and Company (NYSE:LLY)

Colonial River Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 194.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,616 shares of the company’s stock after buying an additional 1,067 shares during the period. Colonial River Wealth Management LLC’s holdings in Eli Lilly and Company were worth $942,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. State Street Corp raised its position in Eli Lilly and Company by 1.9% during the second quarter. State Street Corp now owns 33,878,417 shares of the company’s stock valued at $15,888,300,000 after purchasing an additional 642,274 shares in the last quarter. Morgan Stanley raised its position in Eli Lilly and Company by 0.7% during the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after purchasing an additional 83,915 shares in the last quarter. Northern Trust Corp raised its position in Eli Lilly and Company by 3.6% during the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after purchasing an additional 355,317 shares in the last quarter. Finally, Norges Bank purchased a new stake in Eli Lilly and Company during the fourth quarter valued at about $3,416,206,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.4 %

Shares of NYSE:LLY traded up $3.41 during trading on Tuesday, reaching $763.96. The company’s stock had a trading volume of 2,552,667 shares, compared to its average volume of 3,221,156. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 12 month low of $342.30 and a 12 month high of $800.78. The firm’s 50 day simple moving average is $739.63 and its two-hundred day simple moving average is $641.00. The stock has a market capitalization of $725.88 billion, a PE ratio of 131.72, a price-to-earnings-growth ratio of 1.71 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter last year, the firm earned $2.09 EPS. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year. On average, research analysts predict that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 14,388 shares of the stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $630.28, for a total value of $9,068,468.64. Following the completion of the transaction, the insider now owns 99,754,422 shares of the company’s stock, valued at approximately $62,873,217,098.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 195,055 shares of company stock valued at $125,254,657. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on LLY shares. Truist Financial restated a “buy” rating and set a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Bank of America boosted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $700.00.

Get Our Latest Stock Report on LLY

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.